Is Insulin Growth Factor-Like Family Member 2 (IGFL2) a possible early marker molecule for a successful response to biologic therapy in psoriasis?
Recruiting
- Conditions
- L40.9Psoriasis, unspecified
- Registration Number
- DRKS00031428
- Lead Sponsor
- niklinik RWTH Aachen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
All adult, male and female patients can participate in this study,
- who have severe to moderate psoriasis for which guideline-recommended therapy with one of the following already approved biologics (secukinumab, brodalumab, ixekizumab) is recommended.
- who understand the nature, significance and scope of the study
- who are able to understand and follow the instructions of the study staff
- who have signed an informed consent form
Exclusion Criteria
- Minority
- Pregnancy and breastfeeding
- lack of informed consent
- are incapable of giving consent and / or are unable to understand the nature, significance and scope of the study and to give their consent in writing.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The aim of this research project is to test whether IGFL2 can be a possible early marker gene for a successful response of targeted biologics therapy with secukinumab, ixekizumab or brodalumab in psoriasis vulgaris.
- Secondary Outcome Measures
Name Time Method